Has David Dodgin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $704,240 in general payments to David Dodgin, MD across 110 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Dodgin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Dodgin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Dodgin, MD

Orthopaedic Surgery · Austin, TXNPI 1821047200

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $698,673 of the $704,240 with a category attached, or 99.2%. Zimmer Biomet accounts for 75.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $138,143 and has fallen 71.3% since, to $39,598 in 2025. Among orthopaedic surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$704,240in general payments, 2019–2025

Across 110 payments — averaging $6402.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Zimmer Biomet$528K
Encore Medical, LP$174K
Medinc Of Texas$321
Stryker$305
Smith+Nephew$270
Bioventus LLC$185
plus $774 from 13 others

$90,935in research payments, 2019–2025

Across 51 payments — averaging $1783.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Zimmer Biomet$66K
Encore Medical, LP$25K

What the payments were for

Royalty or licence$698,67399%
Consulting fees$2,4000%
Travel & lodging$1,4360%
Food & beverage$1,7320%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Zimmer Biomet	42	$527,931
Encore Medical, LP	16	$174,455
Medinc Of Texas	1	$321
Stryker	9	$305
Smith+Nephew	8	$270
Bioventus LLC	6	$185
Medacta USA, Inc.	6	$184
Arthrex	2	$164
Abbott	5	$98
Davol Inc.	2	$89
Heron Therapeutics, Inc.	3	$50
Johnson & Johnson	2	$42
Pacira Pharmaceuticals Incorporated	2	$35
Core Surgical Group	1	$24
Orthogenrx Inc.	1	$22
Medline Industries LP	1	$21
Curonix LLC	1	$16
Ultragenyx Pharmaceutical Inc.	1	$16
Moximed, Inc	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$704,240 in reported general payments places this provider in the 95th percentile of 1,337 orthopaedic surgery providers in Texas.

See all orthopaedic surgery providers in Texas →

Medicare billing

Part B allowed, 2024

$387,297

Medicare patients

695

Services billed

6,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	41	$16,492
Celecoxib	292	$7,462
Oxycodone Hcl	323	$1,721
Ondansetron OdtOndansetron	215	$1,547
Tranexamic Acid	159	$1,306
Tramadol Hcl	364	$1,234
Cephalexin	169	$1,162
Cyclobenzaprine Hcl	238	$660
Cefadroxil	107	$586
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	55	$425
Meloxicam	61	$201
Methylprednisolone	21	$113
Tamsulosin Hcl	72	$111
Gabapentin	12	$106
Clindamycin Hcl	18	$49

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Austin

Robert GrahamAustin$6.3M
Eric HeinrichAustin$907K
Stephen BurkhartSan Antonio$185.3M
Kirby HittTemple$9.1M
Richard JonesDallas$6.3M
Stefan KreuzerHouston$6.2M
Michael WirthSan Antonio$4.5M
Stephen IncavoHouston$4.3M
Thomas EdwardsHouston$4.1M
James BrodskyDallas$2.5M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →